Sanofi sounds taps on a half dozen drug pro­grams in lat­est pipeline cleanup

Just 8 months af­ter Sanofi $SNY amend­ed its deal with a cash hun­gry Im­muno­Gen, pay­ing $30 mil­lion to get full com­mer­cial rights on isat­ux­imab and SAR428926 — an an­ti-LAMP1 ADC for sol­id tu­mors — the phar­ma gi­ant is dis­pos­ing a pair of de­vel­op­ment pro­grams once pur­sued for both drugs.

Tout­ed as a po­ten­tial block­buster for mul­ti­ple myelo­ma and a top prospect in their late-stage pipeline, Sanofi is dis­card­ing a mid-stage ef­fort on acute lym­phoblas­tic leukemia for the an­ti-CD38 an­ti­body isat­ux­imab, ac­cord­ing to its pipeline up­date to­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.